ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 793

Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis

Rubén Burgos-Vargas1, Shirley M.L. Tse2, Gerd Horneff3, Aileen L. Pangan4, Kristina Unnebrink5 and Jaclyn K. Anderson4, 1Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 2Pediatric Rheumatology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, juvenile idiopathic arthritis-enthesitis (ERA) and pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the sacroiliac joints and spine. It causes long-term effects on both physical and quality aspects of a child’s life. Adalimumab (ADA) has been previously demonstrated to be effective in polyarticular JIA. The purpose of this study was to evaluate the efficacy and safety of adalimumab compared to placebo in children and adolescents with ERA.  

Methods: This is a phase 3, multicenter, randomized, double-blind (DB) study in patients (pts) aged ≥6 to <18 years (yr) with ERA (ILAR criteria) with active disease not responsive to ≥1 nonsteroidal anti-inflammatory drug and ≥1 disease-modifying antirheumatic drug. Active disease was defined as ≥3 active joints (swelling or loss of motion + pain/tenderness) and enthesitis in ≥1 location. Pts were randomized 2:1 to receive blinded ADA (24 mg/m2BSA up to 40 mg every other week (wk) [eow]) or placebo (PBO) for 12 wks followed by open-label (OL) ADA eow up to 144 wks. The primary endpoint was % change from baseline (BL) in the number of active joints with arthritis (AJC) at wk 12. Secondary variables assessed included enthesitis count (EC), tender and swollen joint counts, and American College of Rheumatology (ACR) Pediatric (Pedi) 30/50/70 responses. Results are summarized through 52 wks of treatment. Safety was assessed in terms of adverse events (AE).  

Results: 46 pts were randomized (31 to ADA, 15 to PBO). No pts discontinued during the DB period; however, 7 pts early escaped to OL ADA. Mean age was 12.9±2.9 yrs. At BL, mean duration of ERA symptoms was 2.6±2.3 yrs; mean AJC was 7.8±6.6, and mean EC was 8.1±8.4. The % change from BL at wk 12 in AJC was greater in the ADA group vs. PBO (-62.6±59.5 vs -11.6±100.5, P=0.039). Most secondary variables showed numerically greater, but not statistically significant improvement at wk 12 in favor of ADA vs. PBO (Table). Treatment response was maintained with continued ADA therapy up to 52 wks (% change from BL at wk 52 in AJC, -88.7±26.1). During the DB period AE incidence rates were similar [ADA/PBO (%)]: any AE (67.7/53.3), serious AE (3.2/0, 1 pt in the ADA group [abdominal pain and headache]), and infectious AEs (29.0/20.0). Among pts who received at least 1 dose of ADA through wk 52, any AE, serious AEs, and infectious AEs were reported in 91.3%, 10.9%, and 76.1%, respectively. No deaths, TB, or malignancies were reported.

At Week 12

 

 

ADA

(N=31)

PBO

(N=15)

Change from Baselinea

(mean ± SD)

# enthesitis sites (0–35)

Tender joint count (0–72)

Swollen joint count (0–68)

-4.4 ± 6.2

-7.9 ± 8.3

-3.5 ± 5.6

-2.7 ± 5.0

-4.5 ± 9.0

-2.4 ± 4.7

ACR Pedi Responseb

(n, %)

ACR Pedi30 responder

ACR Pedi50 responder

ACR Pedi70 responder

21 (67.7)

20 (64.5)

16 (51.6)

10 (66.7)

7 (46.7)

4 (26.7)

aLOCF. bNRI. SD, standard deviation.

Conclusion: ADA reduced the signs and symptoms of ERA at wk 12 and efficacy was sustained up to 52 wks. The safety profile observed in pediatric patients with ERA was consistent with that observed in children aged ≥4­ years treated for polyarticular JIA.


Disclosure:

R. Burgos-Vargas,

AbbVie,

2,

AbbVie, BMS, Pfizer,

5,

AbbVie, BMS, Janssen, Pfizer, Roche,

8;

S. M. L. Tse,

AbbVie, Pfizer,

5;

G. Horneff,

AbbVie, Pfizer, Roche,

2,

AbbVie, Novartis, Pfizer, Roche,

8;

A. L. Pangan,

AbbVie,

1,

AbbVie,

3;

K. Unnebrink,

AbbVie,

1,

AbbVie,

3;

J. K. Anderson,

AbbVie,

1,

AbbVie,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-adalimumab-in-pediatric-patients-with-enthesitis-related-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology